Medicalgorithmics, a Warsaw Stock Exchange-listed leader in cardiac diagnostics software, has accelerated the onboarding of newly acquired clients. By the end of July, the company had completed 28% of the integration process for clients acquired in 2025 (4 out of 14). The activation of new clients – including a European IDTF (Independent Diagnostic Testing Facility) – contributed to a 33% year-over-year increase in the company’s July revenue. These preliminary results further confirm that Medicalgorithmics has entered a phase of dynamic growth, driven by record demand and increasing sales of its proprietary AI-based diagnostic software.
“We are clearly gaining momentum, entering what we view as a more dynamic and sustainable growth trajectory. We are leveraging strong market demand for our unique solutions and have significantly improved our client onboarding efficiency, which has directly translated into revenue growth. Importantly, this growth is primarily driven by recurring revenues from newly signed contracts. This not only validates our strategic focus on scaling sales of our world-class AI software, but also highlights the long-term growth potential of Medicalgorithmics in the coming months,” commented Dr. Kris Siemionow, CEO of Medicalgorithmics.
The year 2025 has brought heightened interest in the company’s offerings and a notable acceleration in client acquisition. Since the beginning of the year, Medicalgorithmics has signed 14 new contracts – already surpassing the total number of new agreements signed in the entire year of 2024. Among the new partnerships are the previously mentioned European IDTF and the company’s first commercial agreement for its VCAST platform, marking an expansion into the strategically important Scandinavian market.
As of June 30th, preliminary estimates indicate strong performance in the U.S. market, with recurring software revenues increasing by 136% year-over-year. All financial figures presented above are preliminary and subject to change following the completion of the Q2 and Q3 2025 financial reporting process.